Merck's Prilosec
Executive Summary
Company confirmed in a Jan. 11 release that it has received an "approvable" letter from FDA covering expanded use of the anti- ulcer drug Prilosec (omeprazole) and that Merck "is in discussion with the agency as to the extent of the new claims." Merck was notified by FDA Dec. 26 that Prilosec is approvable for short-term treatment of active duodenal ulcers poorly responsive to customary medical treatment ("The Pink Sheet" Jan. 7, "In Brief"). Merck said in the release that the approvable letter from FDA "contained an expanded indication that is narrower than that originally recommended in May 1990 by an FDA advisory committee. Merck has not accepted the narrower version and is discussing final language with FDA. Rumors emanating from Europe about Merck withdrawing the application are totally unfounded." Prilosec is approved in the U.S. for treatment of Zollinger-Ellison syndrome and gastroesophageal reflux disease.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth